Article Information
- Received September 2, 2020
- Revision received April 15, 2021
- Accepted April 20, 2021
- Published online April 29, 2021.
Author Information
- Yee Fun Lee1,2,*,
- Lavender Lariviere2,*,
- Alyssa N. Russ2,
- Sang-Zin Choi3,
- Brian J. Bacskai2 and
- Ksenia V. Kastanenka2
- 1Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118
- 2Department of Neurology, MassGeneral Institute of Neurodegenerative Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
- 3NeuroBo Pharmaceuticals, Inc, Boston, MA 02116
- Correspondence should be addressed to Ksenia V. Kastanenka at kkastanenka{at}mgh.harvard.edu.
Author contributions
Author contributions: Y.F.L., A.N.R., B.J.B., and K.V.K. designed research; Y.F.L., L.L., A.N.R., S.-Z.C., and K.V.K. performed research; Y.F.L., L.L., A.N.R., S.-Z.C., and K.V.K. analyzed data; Y.F.L., A.N.R., S.-Z.C., B.J.B., and K.V.K. wrote the paper.
↵* Y.F.L. and L.L. contributed equally to this work.
Disclosures
The authors declare no competing financial interests.
This work was supported by NeuroBo Pharmaceuticals, Dong-A ST; the Korea Drug Development Fund funded by the Ministry of Science, Information and Communication Technology; Future Planning, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (KDDF-201606-03, Republic of Korea); the BrightFocus Foundation Grant A2020833S; the Alzheimer’s Association Grant AARG-18-52336; National Institutes of Health Grants R56AG060974 and R01AG066171.
Funding
HHS | National Institutes of Health (NIH)
R56AG060974; R01AG066171NeuroBo
Dong-A
Alzheimer's Association
AARG18-52336BrightFocus Foundation (BrightFocus)
A2020933S
Other Version
- You are viewing the most recent version of this article.
- previous version (April 29, 2021).
Online Impact